Cardiovasc Ther. 2026;2026(1):e4232591. doi: 10.1155/cdr/4232591.
ABSTRACT
OBJECTIVE: To evaluate the effect of enhanced external counterpulsation (EECP) on cystatin-C in patients with ST-elevation myocardial infarction (STEMI) following primary percutaneous coronary intervention (primary PCI).
METHODS: A total of 436 STEMI patients who underwent primary PCI were enrolled and randomly assigned to the EECP group (n = 211) and the control group (n = 225). The control group received routine treatment alone, and the EECP group was additionally treated with EECP, which was initiated within 4-12 hours and lasted for up to 72 hours after PCI, with one to two sessions per day and 0.5-1 hour per session. Renal function indicators were detected in all patients before primary PCI, as well as at 24, 72 hours, and 5-7 days after PCI. The differences in renal function parameters, cystatin-C, and the incidence of contrast-induced acute kidney injury (CI-AKI) were compared between the two groups.
RESULTS: Compared with the control group, the EECP group presented significantly lower cystatin-C at 24, 72 hours, and 5-7 days after PCI (p < 0.01), lower serum creatinine (Scr) at 24 hours (p = 0.045), and higher estimated glomerular filtration rate (eGFR) (p = 0.025). Post-PCI eGFR decreased markedly in the control group (p < 0.001), whereas no significant difference was observed in the EECP group (p = 0.361). The linear mixed-effects model demonstrated a significant between-group difference in cystatin-C (p < 0.0001), whereas neither the main time effect nor the group-by-time interaction reached statistical significance. Patients in the EECP group exhibited a lower risk of increased cystatin-C (9.5% vs. 4.3%, χ2 = 4.359, p = 0.037). Nevertheless, there was no statistically significant intergroup difference in the incidence of SCr-defined CI-AKI (p = 0.584). Firth penalized logistic regression analysis revealed that EECP was an independent protective factor against elevated cystatin-C (Model 1: OR = 0.45, 95% CI 0.19-0.96, p = 0.037; Model 2: OR = 0.44, 95% CI 0.19-0.94, p = 0.034).
CONCLUSION: EECP can reduce cystatin-C rise after primary PCI in STEMI patients and can represent as a promising intervention targeting biomarkers of early renal injury.
PMID:43034909 | DOI:10.1155/cdr/4232591
